Martin Maly

Dr. Martin Maly

Department of Medicine, First Faculty of Medicine, Charles University in Prague and the Military University Hospital, 16902 Prague, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
VKViktor Kočka
Viktor Kočka
Martin MalyMartin Maly
Martin Maly
PTPetr Toušek
Petr Toušek
TBTomas Buděšínský
Tomas Buděšínský
LLLibor Lisa
Libor Lisa
PWPetr Widimský
Petr Widimský
Bioresorbable vascular scaffolds (BVSs) have been studied in chronic coronary artery disease, but not in acute ST-segment elevation myocardial infarction (STEMI). This prospective multicentre study analysed the feasibility and safety of BVS implantation during primary percutaneous coronary intervention (p-PCI) in STEMI. Bioresorbable vascular scaffold implantation became the default strategy for all consecutive STEMI patients between 15 December 2012 and 30 August 2013. A total of 142 patients underwent p-PCI; 41 of them (28.9%) fulfilled the inclusion/exclusion criteria for BVS implantation. The BVS device success was 98%, thrombolysis in myocardial infarction 3 flow was restored in 95% of patients, and acute scaffold recoil was 9.7%. An optical coherence tomography (OCT) substudy (21 patients) demonstrated excellent procedural results with only a 1.1% rate of scaffold strut malapposition. Edge dissections were present in a 38% of patients, but were small and clinically silent. Reference vessel diameter measured by quantitative coronary angiography was significantly lower than that measured by OCT by 0.29 (±0.56) mm, P = 0.028. Clinical outcomes were compared between BVS group and Control group; the latter was formed by patients who had implanted metallic stent and were in Killip Class I or II. Combined clinical endpoint was defined as death, myocardial infarction, or target vessel revascularization. Event-free survival was the same in both groups; 95% for BVS and 93% for Control group, P = 0.674. Bioresorbable vascular scaffold implantation in acute STEMI is feasible and safe. The procedural results evaluated by angiography and OCT are excellent. The early clinical results are encouraging.

19 May 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
MHMartin Hajsl
Martin Hajsl
AHAlzbeta Hlavackova
Alzbeta Hlavackova
KBKarolina Broulikova
Karolina Broulikova
MSMartin Sramek
Martin Sramek
Martin MalyMartin Maly
Martin Maly
JSJiri Suttnar
Jiri Suttnar
Atherosclerosis is a leading cause of major vascular events, myocardial infarction, and ischemic stroke. Tryptophan (TRP) catabolism was recognized as an important player in inflammation and immune response having together with oxidative stress (OS) significant effects on each phase of atherosclerosis. The aim of the study is to analyze the relationship of plasma levels of TRP metabolites, inflammation, and OS in patients with neurovascular diseases (acute ischemic stroke (AIS), significant carotid artery stenosis (SCAS)) and in healthy controls. Blood samples were collected from 43 patients (25 with SCAS, 18 with AIS) and from 25 healthy controls. The concentrations of twelve TRP metabolites, riboflavin, neopterin (NEO, marker of inflammation), and malondialdehyde (MDA, marker of OS) were measured by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Concentrations of seven TRP metabolites (TRP, kynurenine (KYN), 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA), anthranilic acid (AA), melatonin (MEL), tryptamine (TA)), NEO, and MDA were significantly different in the studied groups. Significantly lower concentrations of TRP, KYN, 3-HAA, MEL, TA, and higher MDA concentrations were found in AIS compared to SCAS patients. MDA concentration was higher in both AIS and SCAS group (p < 0.001, p = 0.004, respectively) compared to controls, NEO concentration was enhanced (p < 0.003) in AIS. MDA did not directly correlate with TRP metabolites in the study groups, except for 1) a negative correlation with kynurenine acid and 2) the activity of kynurenine aminotransferase in AIS patients (r = −0.552, p = 0.018; r = −0.504, p = 0.033, respectively). In summary, TRP metabolism is clearly more deregulated in AIS compared to SCAS patients; the effect of TRP metabolites on OS should be further elucidated.

1 April 2024 in Stroke
Verified
Journal Article
Open access
PDF file
LMLuca Mengozzi
Luca Mengozzi
IBIlaria Barison
Ilaria Barison
Martin MalyMartin Maly
Martin Maly
Giulia LorenzoniGiulia Lorenzoni
Giulia Lorenzoni
Marny FedrigoMarny Fedrigo
Marny Fedrigo
AAAnnalisa Angelini
Annalisa Angelini
BACKGROUND: Thrombosis is linked to neutrophil release of neutrophil extracellular traps (NETs). NETs are proposed as a mechanism of resistance to thrombolysis. This study intends to analyze the composition of thrombi retrieved after mechanical thrombectomy, estimate the age and organization of thrombi, and evaluate associations with the use of thrombolysis, antiplatelets, and heparin. METHODS: This retrospective observational study involved 72 samples (44 from cerebral and 28 coronary arteries), which were stained with hematoxylin and eosin, anti-NE (neutrophil elastase) antibody, and anti-histone H2B (histone H2B) antibody, representing different components in NET formation, all detectable during the later stages of NETosis, for histochemical and digital quantification of NET content. The histological and morphological evaluations of the specimens were correlated, through univariate and mediation analyses, with clinical information and therapy administered before intervention. RESULTS: The results demonstrated that the composition of cerebral and coronary thrombi differs, and there were significantly more lytic cerebral thrombi than coronary thrombi (66% versus 14%; P =0.005). There was a considerably higher expression of NETs in the cerebral thrombi as testified by the higher expression of H2B ( P =0.031). Thrombolysis was remarkably associated with higher NE positivity (average marginal effect, 6.461 [95% CI, 0.7901–12.13]; P =0.02555), regardless of the origin of thrombi. There was no notable association between the administration of antiaggregant therapy/heparin and H2B/NE amount when adjusted for the thrombus location. Importantly, the age of the thrombus was the only independent predictor of NET content without any mediation of the thrombolytic treatment ( P =0.014). CONCLUSIONS: The age of the thrombus is the driving force for NET content, which correlates with impaired clinical outcomes. The therapy that is currently administered does not modify NET content. This study supports the need to investigate new pharmacological approaches added to thrombolysis to prevent NET formation or enhance their disruption, such as recombinant human DNase I (deoxyribonuclease I).

1 June 2011 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
PMPavel Májek
Pavel Májek
ZRZuzana Reicheltová
Zuzana Reicheltová
JSJiri Suttnar
Jiri Suttnar
Martin MalyMartin Maly
Martin Maly
MOMilan Oravec
Milan Oravec
Jan E. DyrJan E. Dyr
Jan E. Dyr
The aim of this proteomic study was to look for changes taking place in plasma proteomes of patients with acute myocardial infarction (AMI), unstable angina pectoris (UAP), and stable angina pectoris (SAP).

1 September 2009 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JVJosef Veselka
Josef Veselka
DZDavid Zemánek
David Zemánek
PHPetr Hájek
Petr Hájek
Martin MalyMartin Maly
Martin Maly
RARadka Adlová
Radka Adlová
DTDavid Tesař
David Tesař

1 December 2009 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
ASAlžběta Sobotková
Alžběta Sobotková
LMLeona Mášová-Chrastinová
Leona Mášová-Chrastinová
JSJiří Suttnar
Jiří Suttnar
JŠJana Štikarová
Jana Štikarová
PMPavel Májek
Pavel Májek
JDJan E. Dyr
Jan E. Dyr